News Archive

April 24, 2024

Day One’s Ojemda Gets FDA Accelerated Approval for Pediatric Brain Tumor

  • Portfolio Company News
Read more
April 24, 2024

Deconstructing the Diligence Process: An Approach to Vetting New Product Theses

  • From the Trenches
Read more
April 9, 2024

Two ex-bluebird leaders launch Nvelop with $100M to tackle the biggest problem in gene editing

  • Portfolio Company News
Read more
April 3, 2024

Obsidian Therapeutics rakes in $160M for solid tumor cell therapy program

  • Portfolio Company News
Read more
April 3, 2024

Diagonal Therapeutics Raises $128 Million to Discover Agonist Antibodies

  • Portfolio Company News
Read more